Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval

Executive Summary

FDA signaled during an advisory committee on Orexigen's weight-loss drug Contrave that it could be ready to revise its obesity drug draft guidance, particularly with regard to cardiovascular goals, but stressed that for now, the drugs under review are to be judged by standards articulated in the draft document.
Advertisement

Related Content

Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Committee On CV Risk
Complaints To CDER Down, But Lorcaserin Weighs Heavily At Ombudsman's Office
Obesity Drug Developers Aim To Navigate Regulatory Backroads
Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
Where FDA Is Paying The Most Attention: Drug Safety Advisory Committee Had The Most Meetings In 2010
The Skinny On The Obesity Drug Advisory Committees: A Look At The Panelists' Votes
Positive Panel Recommendation For Contrave Could Change Obesity Drug Game
Orexigen Offers Robust Contrave Risk Plan To Monitor For Safety Concerns
The Skinny On The Obesity Drug Advisory Committees: A Look At The Panelists' Votes
FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance

Topics

Advertisement
UsernamePublicRestriction

Register

PS052935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel